Immix Biopharma (NASDAQ:IMMX) is a clinical‐stage biotechnology company developing a proprietary class of polymer‐conjugate therapeutics designed to improve the delivery and efficacy of anti‐cancer agents. The company’s platform leverages water‐soluble polymer backbones that can be selectively loaded with cytotoxic drugs, enabling enhanced tumor targeting, controlled drug release and reduced systemic toxicity. Immix’s lead candidate, IMX‐110, combines a potent chemotherapy payload with polymer technology to address treatment‐resistant solid tumors and hematologic malignancies, with ongoing studies in ovarian cancer, pancreatic cancer and acute myeloid leukemia.
In addition to IMX‐110, Immix Biopharma is advancing a second program, IMX‐017, which utilizes the same polymer conjugation approach to deliver novel chemotherapeutic agents. Preclinical data indicate that polymer conjugation enhances the pharmacokinetic profile of small‐molecule drugs, prolonging circulation time and improving penetration of tumor tissue. The company’s development strategy includes both stand‐alone administration and combination regimens to maximize therapeutic benefit while limiting off‐target effects.
Founded in 2013 and headquartered in San Antonio, Texas, Immix Biopharma conducts its research and development activities across key U.S. and European oncology centers. The company’s robust preclinical and clinical collaborations with academic institutions and contract research organizations support its efforts to advance pipeline candidates through regulatory milestones. Immix is committed to expanding its geographic reach, with plans to initiate multi‐site clinical trials in North America and select European markets.
Immix Biopharma is led by a management team and board of directors with extensive experience in oncology drug development, clinical operations and regulatory affairs. The leadership group includes veterans from leading pharmaceutical and biotechnology firms, ensuring strategic guidance in advancing Immix’s innovative polymer‐conjugate platform from early‐stage research to late‐stage clinical evaluation.
